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Abstract
Background: Alternative pre-mRNA splicing (AS) plays a central role in generating complex proteomes and influences
development and disease. However, the regulation and etiology of AS in human tumorigenesis is not well understood.
Methodology/Principal Findings: A Basic Local Alignment Search Tool database was constructed for the expressed
sequence tags (ESTs) from all available databases of human cancer and normal tissues. An insertion or deletion in the
alignment of EST/EST was used to identify alternatively spliced transcripts. Alignment of the ESTs with the genomic
sequence was further used to confirm AS. Alternatively spliced transcripts in each tissue were then subtractively cross-
screened to obtain tissue-specific variants. We systematically identified and characterized cancer/tissue-specific and
alternatively spliced variants in the human genome based on a global view. We identified 15,093 cancer-specific variants of
9,989 genes from 27 types of human cancers and 14,376 normal tissue-specific variants of 7,240 genes from 35 normal
tissues, which cover the main types of human tumors and normal tissues. Approximately 70% of these transcripts are novel.
These data were integrated into a database HCSAS (http://202.114.72.39/database/human.html, pass:68756253). Moreover,
we observed that the cancer-specific AS of both oncogenes and tumor suppressor genes are associated with specific cancer
types. Cancer shows a preference in the selection of alternative splice-sites and utilization of alternative splicing types.
Conclusions/Significance: These features of human cancer, together with the discovery of huge numbers of novel splice
forms for cancer-associated genes, suggest an important and global role of cancer-specific AS during human tumorigenesis.
We advise the use of cancer-specific alternative splicing as a potential source of new diagnostic, prognostic, predictive, and
therapeutic tools for human cancer. The global view of cancer-specific AS is not only useful for exploring the complexity of
the cancer transcriptome but also widens the eyeshot of clinical research.
Citation: He C, Zhou F, Zuo Z, Cheng H, Zhou R (2009) A Global View of Cancer-Specific Transcript Variants by Subtractive Transcriptome-Wide Analysis. PLoS
ONE 4(3): e4732. doi:10.1371/journal.pone.0004732
Editor: Joseph Alan Bauer, Cleveland Clinic, United States of America
Received November 6, 2008; Accepted January 29, 2009; Published March 6, 2009
Copyright:  2009 He et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by the National Natural Science Foundation of China, the National Key Basic Research project (2006CB102103,
2004CB117401), the Program for New Century Excellent Talents in University, and the 111 project #B06018. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hhcheng@whu.edu.cn (HC); rjzhou@whu.edu.cn (RZ)
Introduction
It remains unknown how both intron removal and exon
rearrangement are precisely regulated to produce correct
proteomes in a cell type- or developmental stage-specific manner.
Alternative splicing, the process by which the exons of primary
transcripts can be spliced into different arrangements to produce
structurally and functionally distinct mRNA and protein variants,
is the most widely used mechanism to enhance the protein
diversity of higher eukaryotic organisms. It has been estimated that
35%–94% of all human genes appear to undergo alternative
splicing [1–7], suggesting that this mechanism has a major role in
generating protein diversity. As sequence data continue to be
generated from projects at an ever-increasing rate, the need for
mining the data and constructing a repository for transcriptome
information continues to grow as well.
In many pathological conditions, aberrantly spliced pre-mRNAs
are generated because they escape the quality control mechanisms
within cells (e.g. the nonsense mediated mRNA decay pathway)
and are, therefore, translated into aberrant proteins involved in
human diseases, including cancer [8–11]. It is estimated that
approximately 60% of disease mutations in the human genome are
splicing mutations [12,13]. Currently, the analysis of cancer-
specific alternative splicing is a promising step forward and
potential source of new clinical diagnostic, prognostic, and
therapeutic strategies. Evidence is accumulating that supports a
connection between tumorigenesis and alternative splicing [14–
18]. Using bioinformatic approaches, Xu and Lee discovered
cancer-specific splice variants in 316 genes [19]. We previously
identified testis-/testis cancer-specific splice variants using bioin-
formatic and experimental approaches [20].
Despite the growing interest in the impact of alternative splicing
in various aspects of the biological processes, our understanding of
alternative splicing is still scattered, and its general regulatory
mechanisms, especially in tumorigenesis, are not well known
[21,22]. However, it is believed that cancer-specific splice variants
could be involved in the etiopathogeny of many diseases and some
might serve as diagnostic or prognostic markers. Moreover, the
direct targeting of protein is probably an advantageous way of
correcting cancer-associated splicing alterations. For example, the
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for specific antibodies conjugated to tumor cell toxins for cancer
treatments. The etiopathogeny concerning the cancer-specific AS
and all related applications need to be explored further.
In order to advance our understanding of the biological
significance of alternative splicing in human cancers, it is essential
to systematically identify cancer-specific splicing events at the
transcriptome level. In the present study, we performed a genome-
wide analysis of alternative splicing in human cancer and normal
tissues using an intersection/subtractive model consisting of the
following steps: 1) identifying insertions or deletions in the
alignments of expressed sequence tags (ESTs) to identify alternative
splicing transcripts based on a previously described method [2], 2)
the alignment of EST/genome to confirm the transcripts, and 3)
obtaining the tissue-specific and alternatively spliced variants by
subtractively cross-screening the alternatively spliced transcripts in
each tissue. Our results distinguish distinctive patterns of cancer-
specific alternative splicing and identify a large number of cancer-
and tissue-specific splicing isoforms, which provides a global view of
human cancer-specific alternative splicing in a large-scale approach
and a potential source of new clinical diagnostic, prognostic, and
therapeutic strategies for human cancer.
Materials and Methods
Data sources and filtration
Human EST data for both cancerous and normal tissues were
drawn from the Cancer Genome Anatomy Project (CGAP)
(http://cgap.nci.nih.gov/Tissues/LibraryFinder). The CGAP col-
lects EST libraries from all over the world and provides good tissue
information. All available EST libraries for both human cancer
and normal tissues were downloaded from the CGAP libraries,
Mammalian Gene Collection libraries, and Open Reading Frame
EST Sequencing libraries. We sought to avoid mixing multiple
tissues. Among these libraries, those signed ‘pooled’ were excluded
because these procedures affect tissue classification. For normal
tissue, ESTs were classified in accordance with the developmental
Table 1. Numbers of libraries and ESTs in cancers.
Cancer types (27 types) Libraries ESTs
adrenal_cancer 3 10431
bone_marrow_leukemia 21 43943
brain_glioma 43 75546
brain_meningioma 7 860
brain_cancer 213 39845
breast_cancer 792 143423
cervical_cancer 32 48606
chondrosarcoma 15 49638
colorectal_cancer 803 185632
esophageal_cancer 17 15039
germ_cell_cancer 30 161682
head_and_neck_cancer 291 93978
kidney_cancer 87 74290
liver_cancer 62 117276
lung_cancer 220 126775
lymphoma 6 12458
muscle_tissue_cancer 26 83411
ovarian_cancer 162 98087
pancreas_insulinoma 1 33046
pancreatic_cancer 22 82994
primitive_neuroectodermal_cancer_of_CNS 23 72677
prostate_cancer 169 168151
prostatic_intraepithelial_neoplasia 5 9569
retinoblastoma 3 51568
skin_cancer 36 137803
stomach_cancer 244 94950
uterus_cancer 110 46624
Total 3,443 2,078,302
doi:10.1371/journal.pone.0004732.t001
Table 2. Numbers of libraries and ESTs in normal tissues.
Tissue type (35 tissues) Libraries ESTs
bone-adult 2 1965
brain-adult 368 130619
brain-fetus 73 174889
brain-infant 11 73726
colon-adult 133 25757
colon-fetus 1 5
eye-adult 33 100173
eye-fetus 7 19659
heart-adult 10 3979
heart-fetus 13 62681
kidney-fetus 16 13947
liver-adult 11 29818
liver-fetus 22 142750
lung-adult 92 44457
lung-fetus 18 35607
mammary-gland-adult 331 68603
muscle-adult 10 70211
muscle-fetus 4 2235
ovary-adult 6 8126
pancreas-adult 10 24759
pancreas-fetus 2 5545
peripheral-nerve-adult 1 6571
peripheral-nerve-juvenile 1 9482
pituitary-gland-adult 6 8520
placenta-adult 358 268277
prostate-adult 127 53220
skin-infant 3 10319
spleen-adult 3 1841
spleen-fetus 1 1332
stomach-adult 67 10417
stomach-fetus 2 9
testis-adult 157 30549
thyroid-adult 78 13314
uterus-adult 10 35026
vascular-adult 5 8451
Total 1,992 1,496,839
doi:10.1371/journal.pone.0004732.t002
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used. All EST and library data on different tissues that were used
are listed in Tables 1 and 2.
All collection data were then dealt with in three procedures:
repeat sequence masking to remove simple repeats in the dataset
(program, repeatmasker; repeat database, repbase; girnst ser-
ver:www.girinst.org), vector and contamination masking to clean
the vector sequences (program, crossmatch; vector database,
UniVec_Core; National Center for Biotechnology Information
ftp server: ftp://ftp.ncbi.nih.gov/), and a final cleaning of short
and rubbish sequences (program, seqclean from egassembler
server: http://egassembler.hgc.jp). Any Alu repeats were included
in, and the filtered ESTs were available for the following analysis.
Computational procedures to identify cancer/tissue-
specific alternative splicing
A basic local alignment search tool (BLAST) database was
constructed for the ESTs of each tissue. Alternative splicing was
analyzed based on a previous method [2]. Transcripts specific to
tissue T were identified based on an intersection/subtractive
model:
TS~T{T\O
Where TS is the alternatively spliced transcripts specific to tissue
T, T is all transcripts in tissue T, and O is all transcripts in the
other tissues (>, intersection).
Briefly, the three steps were as follows:
(1) Tissue T’s EST dataset was BLASTed against itself. The e-
value was set to 1e-30. Gaps (insertion or deletion) in the
ESTs were identified after alignment. Parameters to identify
Table 3. Numbers of cancer-specific AS transcripts and their
genes.
Cancer types (27 types) Genes Transcripts Transcripts/Gene
adrenal_cancer 61 80 1.31
bone_marrow_leukemia 237 356 1.50
brain_glioma 485 720 1.48
brain_meningioma 1 1 1.00
brain_cancer 22 30 1.36
breast_cancer 550 757 1.38
cervical_cancer 316 428 1.35
chondrosarcoma 239 352 1.47
colorectal_cancer 397 578 1.46
esophageal_cancer 175 226 1.29
germ_cell_cancer 1307 2167 1.66
head_and_neck_cancer 135 182 1.35
kidney_cancer 467 716 1.53
liver_cancer 950 1410 1.48
lung_cancer 605 880 1.45
lymphoma 16 21 1.31
muscle_tissue_cancer 692 1044 1.51
ovarian_cancer 351 512 1.46
pancreas_insulinoma 45 76 1.69
pancreatic_cancer 426 643 1.51
primitive_neuroectodermal_
cancer_of_CNS
659 1018 1.54
prostate_cancer 92 111 1.21
prostatic_intraepithelial_
neoplasia
11 18 1.64
retinoblastoma 434 705 1.62
skin_cancer 939 1557 1.66
stomach_cancer 249 326 1.31
uterus_cancer 128 179 1.40
Total 9,989 15,093 1.51
doi:10.1371/journal.pone.0004732.t003
Table 4. Numbers of normal tissue-specific AS transcripts and
their genes.
Tissue types (35 tissues) Genes Transcripts Transcripts/Gene
bone-adult 1 2 2
brain-adult 924 1613 1.75
brain-fetus 2231 5545 2.49
brain-infant 53 72 1.36
colon-adult 17 22 1.29
colon-fetus 1 2 2.00
eye-adult 582 907 1.56
eye-fetus 58 76 1.31
heart-adult 6 9 1.50
heart-fetus 100 146 1.46
kidney-fetus 110 142 1.29
liver-adult 335 961 2.87
liver-fetus 292 506 1.73
lung-adult 78 160 2.05
lung-fetus 110 152 1.38
mammary-adult 41 57 1.39
muscle-adult 250 384 1.54
muscle-fetus 18 27 1.50
ovary-adult 19 26 1.37
pancreas-adult 28 39 1.39
pancreas-fetus 23 33 1.43
peripheral-nerve-adult 18 23 1.28
peripheral-nerve-juvenile 18 23 1.28
pituitary-gland-adult 28 84 3.00
placenta-adult 1567 2902 1.85
prostate-adult 102 162 1.59
skin-infant 99 121 1.22
spleen-adult 2 2 1.00
spleen-fetus 1 1 1.00
stomach-adult 3 5 1.67
stomach-fetus 1 6 6.00
testis-adult 47 73 1.55
thyroid-adult 16 20 1.25
uterus-adult 51 63 1.2
vascular-adult 10 10 1.00
Total 7240 14,376 1.99
doi:10.1371/journal.pone.0004732.t004
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(2) Tissue T’s ESTs were BLASTed against the ESTs of the other
tissues. Parameters were the same as step 1.
(3) Subtractive ESTs were identified as tissue T-specific ESTs by
insertion/deletion comparisons after BLAST. Computer
programs were written using the Perl language.
EST/genomic sequence alignments, chromosome
mapping, and splice site analysis
To decrease errors in EST alignments and determine the
chromosomal loci of each gene, we localized ESTs to genomic
sequences using BLAST-like alignment tools (http://genome.ucsc.
edu). We used the default parameters and selected the best score
results. The exon position on the chromosome was recorded for
each transcript and used to determine splice sites and gene
structure. Splice sites for both 59 and 39 exon/intron boundaries
were aligned online via http://weblogo.berkeley.edu/logo.cgi. We
allowed an error of 10 bp in the exon/intron boundary. Based on
comparisons of EST/genomic alignments, two possible errors can
be checked: (i) if the candidate EST in the same gene was not on
the same chromosome and (ii) is the candidate EST in the same
gene was not in the same locus on the chromosome. The reasons
for these errors mainly included EST sequencing errors,
pseudogenes, and multiple copy genes. The two cases were
excluded as false positives in the final database.
Function classification of alternative splicing
Each alternatively spliced EST was BLASTed to the RefSeq
mRNA database (expectations 1e-30) to identify the corresponding
genes. Using PANTHER (http://www.pantherdb.org/tools/
genexAnalysis.jsp), these genes were clustered by the gene
ontology (GO) process. We also searched the Entrez Gene
Database to correct our results.
Alternative splicing database construction
We input all prediction results into the local alternative splicing
database. This database was constructed with MySql and pro-
grammed by Perl and CGI. All information such as gene ID, gene
structure, EST accession, mRNA accession, gene information, and
exon location on the chromosome were collected in the database.
Figure 1. A schematic representation of cancer-specific alternative gene splicing. (a) Brain cancer (gene ACYl), (b) breast cancer (SRP19),
(c) liver cancer (CDK5), (d) lung cancer (CDKN1A), and (e) prostate cancer (SMS). Cancer-specific isoforms are showed on the bottom in each panel.
The biological processes of these transcripts (GO process) are indicated on the right. Deleted domains are shown with blue arrows. Arrows with a
right angle indicate the start codon, ATG.
doi:10.1371/journal.pone.0004732.g001
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Gene ID Symbol Gene Description AS
Oncogenes
25 ABL1 v-abl Abelson murine leukemia viral oncogene homolog 1 1
3726 JUNB jun B proto-oncogene 2
7409 VAV1 vav 1 oncogene 1
6757 SSX2 synovial sarcoma, X breakpoint 2 3
2130 EWSR1 Ewing sarcoma breakpoint region 1 3
2241 FER fer (fps/fes related) tyrosine kinase (phosphoprotein NCP94) 2
369 ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1
4613 MYCN v-myc myelocytomatosis viral related oncogene 2
2534 FYN FYN oncogene related to SRC, FGR, YES 2
727735 unassigned similar to TBC1 domain family member 3 1
51513 ETV7 ets variant gene 7 (TEL2 oncogene) 2
5894 RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 2
4193 MDM2 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein 1
4609 MYC v-myc myelocytomatosis viral oncogene homolog 1
2353 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 3
7410 VAV2 vav 2 oncogene 1
4194 MDM4 Mdm4, transformed 3T3 cell double minute 4, p53 binding protein 1
2118 ETV4 ets variant gene 4 (E1A enhancer binding protein, E1AF) 3
598 BCL2L1 BCL2-like 1 3
55885 LMO3 LIM domain only 3 (rhombotin-like 2) 1
3265 HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 2
4893 NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 1
Total 39
Tumor suppressors
5934 RBL2 retinoblastoma-like 2 (p130) 1
3482 IGF2R insulin-like growth factor 2 receptor 1
5925 RB1 retinoblastoma 1 (including osteosarcoma) 1
54984 unassigned PIN2-interacting protein 1 1
4017 LOXL2 lysyl oxidase-like 2 3
29997 GLTSCR2 glioma tumor suppressor candidate region gene 2 3
2014 EMP3 epithelial membrane protein 3 1
672 BRCA1 breast cancer 1, early onset 2
54879 ST7L suppression of cancerigenicity 7 like 2
51147 ING4 inhibitor of growth family, member 4 1
7982 ST7 suppression of cancerigenicity 7 1
51566 ARMCX3 armadillo repeat containing, X-linked 3 4
84695 LOXL3 lysyl oxidase-like 3 2
79961 DENND2D DENN/MADD domain containing 2D 2
7157 TP53 cancer protein p53 (Li-Fraumeni syndrome) 1
7248 TSC1 tuberous sclerosis 1 1
54768 HYDIN hydrocephalus inducing homolog 3
581 BAX BCL2-associated X protein 1
1026 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 5
1029 CDKN2A cyclin-dependent kinase inhibitor 2A 1
10263 CDK2AP2 CDK2-associated protein 2 1
Total 38
doi:10.1371/journal.pone.0004732.t005
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HCSAS: A database for cancer-specific alternative splicing
For analyzing cancer-specific alternative splicing, we carefully
classified all available EST libraries into 35 distinct normal tissue
classes and 27 types of cancer to avoid mixing multiple tissues. Our
final classification consisted of 1,992 libraries with 1,496,839 ESTs
for normal human samples and 3,443 libraries with 2,078,302
ESTs for cancer samples (Tables 1 and 2). Through computa-
tionally subtractive analysis, we detected 15,093 cancer-specific
transcripts in 9,989 genes from the 27 types of cancer, and 14,376
normal tissue-specific transcripts in 7,240 genes from the 35 tissues
(Tables 3 and 4), which cover the main types of human tumors and
tissues. Cancer-specific transcript numbers per gene detected were
1 to 1.69 with an average of 1.51, whereas there were 1 to 6
normal tissue-specific transcripts with an average of 1.99 (Tables 3
and 4), indicating fewer alternative splicing events (cancer-specific)
in cancer compared to normal tissues.
To facilitate future studies and referencing of alternatively
spliced genes, for both human cancer and normal tissues, we
Figure 2. A schematic representation of cancer-specific alternative gene splicing. (a) Oncogene, (b) tumor suppressor gene. The
alternative splicing of RAF1 generates a lung cancer-specific transcript, whereas the alternative splicing of FOS produces an uterus cancer-specific
transcript. Tumor suppressor GLTSCR2 is alternatively spliced to produce two retinoblastoma-specific transcripts and EMP3 to generate a skin cancer-
specific transcript. Deleted domains are shown with blue arrows. Arrows with a right angle indicate the start codon, ATG.
doi:10.1371/journal.pone.0004732.g002
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splicing database (HCSAS) based on our analysis, which was
divided into two parts: cancer-specific (15,093 transcripts) and
normal tissue-specific (14,376) alternative splicing. Of these
cancer- or tissue-specific AS, approximately 70% are novel
isoforms. For example, in brain cancer, because of the alternative
splicing and deletion of domain of the peptidase m20 family
member, the aminoacylase-1 gene (ACY1) was spliced to produce
a brain cancer-specific transcript (Figure 1a), and alternative
splicing occurs in the SRP19 gene to produce a breast cancer-
specific transcript by an alternative deletion of exon 3 (Figure 1b).
Similarly, in liver cancer, lung cancer, and prostate cancer,
cancer-specific isoforms were detected in our subtractive screening
(Figure 1c–e).
Furthermore, we systematically identified cancer-specific tran-
scripts in both oncogenes and tumor suppressors. Thirty-nine
oncogene isoforms and 38 tumor suppressor gene isoforms with
cancer-specific AS events were detected (Table 5). For example,
we identified a lung cancer-specific transcript in the oncogene
RAF1 with a deletion of the Raf-like Ras-binding domain, an
uterus cancer-specific transcript in oncogene FOS (Figure 2a), and
a retinoblastoma-specific transcript in the tumor suppressor
GLTSCR2, and a skin-cancer-specific transcript in the tumor
suppressor EMP3 (Figure 2b).
The HCSAS database presents a global overview of cancer-
specific alternative splicing in humans and is essential for
understanding tumorigenesis at a systematic level. The main
information in this database includes the specific alternative
splicing in both cancer and normal tissues, gene ID, gene
structure, splicing sites, chromosome localization, DNA and
protein sequences linked with the NCBI website, and GO process,
function, and subcellular localization. An example page set shows
the details of an adrenal cancer gene, FDPS (Figure 3). The
HCSAS database can be accessed at http://202.114.72.39/
database/human.html.
Biased utilization of alternative splicing types in cancer
An examination of cancer-specific alternative splicing revealed a
biased distribution of alternative splicing types in cancer. Both the
alternative 39 splice site and 59 splice site were used more often in
cancer; however, a lower proportion of intron retention and
cassette alternative exon occurred in cancer tissues compared to
normal tissues (Figure 4b). Moreover, alternative splicing types
differ between different kinds of cancer (Figure 4a). For example,
in liver cancer, breast cancer, and prostate cancer, intron retention
decreased and cassette alternative exons increased significantly,
whereas in uterus cancer and skin cancer, cassette alternative
exons markedly decreased.
Preference in the selection of alternative splice sites in
cancer
To explore the preference/diversification of alternative splice
sites in cancer, we analyzed all splice sites in the 27 types of cancer
and 35 normal tissues by comparing each EST with its genomic
sequence and mapping it onto the chromosome. We detected five
basic donor-acceptor splice sites: GT-AG, CT-AC, GC-AG, GG-
AG, and GT-GG, of which GT-AG are the most dominant sites.
Figure 3. A database of cancer- and normal tissue-specific alternative splicing. An example page set from the database shows the details
of an adrenal cancer gene, FDPS. The information includes the specific alternative splicing of both cancer and normal tissues, gene ID, gene structure,
splicing sites, chromosome localization, DNA and protein sequences linked with the NCBI website, and GO process, function, and subcellular
localization.
doi:10.1371/journal.pone.0004732.g003
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cancer uses rare splice sites and GT-AG more frequently, but less
CT-AC compared to normal tissues (Figure 5a, b). Moreover, the
selection of splice sites differs between different kinds of cancer
(Figure 5c). For example, CT-AC sites are seldom used in breast
cancer, liver cancer, lung cancer, and prostate cancer; in liver
cancer, 59 sites of rare splicing are almost AA.
Association of cancer-specific alternative splicing of both
oncogenes and tumor suppressor genes with cancer
Although both oncogenes and tumor suppressors are thought to
be vital factors in tumorigenesis, we sought to identify cancer-
specific variants and their possible involvement in cancer. We
observed that oncogenes with cancer-specific AS are more often
present in ovary cancer (6 oncogenes) and muscle cancer (5
oncogenes), whereas tumor suppressor genes with cancer-specific
AS are more frequent in germ cell cancer (6), skin cancer (5), and
primitive neuroectodermal cancer (5) (Figure 6). Some oncogenes
and tumor suppressors with cancer-specific alternative splicing,
such as EWSR1, CDKN1A, and GLTSCR2, are present in more
types of cancer. Moreover, neither oncogenes nor tumor
suppressors with cancer-specific AS were detected in brain cancer,
prostate cancer, adrenal cancer, or lymphoma. This distribution
bias for cancer-specific AS implies that the cancer-specific
Figure 4. The frequencies (percentages) of the five types of cancer- and normal tissue-specific alternative splicing. (a) 16 types of
human cancer and 17 normal tissues, (b) the average values between tumors and normal tissues. The five colors indicate the five types of tissue-
specific alternative splicing: cassette alternative exon, alternative 59 splice site, alternative 39 splice site, intron retention, and mutually exclusive
alternative exons. Yellowish regions indicate over 30% of the frequencies.
doi:10.1371/journal.pone.0004732.g004
Transcribed Cancer Variants
PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4732alternative splicing of both oncogenes and tumor suppressor genes
is associated with specific cancer types.
Biological relevance of the cancer-specific transcripts in
the diversification of protein functions
The cancer-specific transcripts were classified based on gene
function by searching the RefSeq database and GO. We classified
15,093 cancer-specific transcripts from 9,989 genes into 15
function groups. Protein metabolism and modification, and
nucleic acid metabolism are the most prevalent functional
processes in cancer. However, the function groups of these
cancer-specific transcripts differ in different cancers. For example,
the least common process in breast cancer is pre-mRNA
processing, whereas the function groups of cell communication
and lipid, fatty acid, and steroid metabolism are seldom found in
prostate cancer (Figure 7).
Discussion
The complexity of the transcriptome has been underestimated.
In this paper, we described the transcriptome-wide identification
and characterization of cancer-specific and alternatively spliced
variants in human cancer based on a global view of cancer-specific
alternative splicing developed by subtractive transcriptome-wide
analysis. Based on an intersection/subtractive model, we have
developed an analysis method for precisely screening cancer-
specific alternative splicing. The EST sequences were aligned first,
compared with their genomic sequences, and then mapped onto
chromosomes. These procedures eliminated many EST errors,
pseudogene, and multiple-copy/repeat gene problems when data
were from diverse EST databases. Finally, the alternatively spliced
transcripts were subject to the subtractive screening of a tissue
versus all other tissues, and these analyses finally yielded cancer-
specific transcripts. We identified a large number of cancer- /
normal tissue-specific transcripts. Beyond all doubt, this is an
abundant resource for research and the development of new
diagnostic, prognostic, predictive, and therapeutic tools against
human cancer. Furthermore, these resources are integrated into
an available database. The HCSAS database presents a global
overview of cancer-specific alternative splicing in humans and is
essential for understanding tumorigenesis at a systematic level.
There are two main approaches for the global analysis of
alternative splicing. First, based on the availability of sequenced
genomes and large databases of sequenced transcripts (ESTs and
cDNAs), alternative splicing events may be searched through
reciprocal transcript alignments and alignments to genomic
sequences. Several analyses in this manner have been reported
[6,23–29]. Because of its major limitation of EST coverage bias, a
microarray-based technology has been developed to search for the
alternative splicing events [3,30–36]. Large sets of oligonucleotide
probes may be designed specifically for individual exons and/or
splice junction sequences, which allow the identification of new AS
events. Here we have further developed a systematic method to
search for cancer- or tissue-specific AS events in transcriptomes
based on the intersection/subtractive screening analyses of
transcriptomes, which is especially useful for identifying cancer/
Figure 5. Percentages of the types of alternative splice sites. The splice sites include GT-AG, GC-AG, GG-AG, GT-GG, and the others (a)i n
human cancer (b) and normal tissues. (c) Percentage distribution of the splice sites in five types of cancer and normal tissues (brain, breast, lung, liver,
and prostate).
doi:10.1371/journal.pone.0004732.g005
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cancer-specific isoforms were identified for the main human
cancers. Nevertheless, these transcripts need to be further
confirmed for their cancer/tissue specialization. RT-PCR tech-
nology and/or microarrays may be useful screening tools for this
analysis.
Based on the transcriptome-wide analysis, we did observe
special patterns of cancer-specific alternative splicing. 1) Less
cancer-specific AS events occur in cancer compared to normal
tissues. 2) Cancer possesses distribution bias for alternative splicing
types. 3) Cancer uses rare splice sites and GT-AG more frequently,
but less CT-AC compared to normal tissues. 4) The selection of
splice sites differs between different kinds of cancer. 5) The cancer-
specific alternative splicing of both oncogenes and tumor
suppressor genes is associated with the specific cancer type. And
finally, the functional groups of these cancer-specific transcripts
differ in different cancers, indicating that individual cancers prefer
combination controls of pathways in preference of using AS in
tumorigenesis. These special features of human cancers indicate
that 1) the cellular splicing machinery is changed during the
transformation from normal to cancerous, 2) alternative splicing
plays an important role during tumorigenesis, and 3) individual
cancers have unique regulatory combinations at the alternative
splicing level, which further support the prediction that approx-
imately 60% of disease mutations in the human genome are
splicing mutations [12,13]. Our data includes the discovery of
many novel splice forms of cancer-associated genes and alterna-
tive-splicing patterns in cancer, and it suggests a significant new
direction for human cancer research. We strongly advise the use of
cancer-specific alternative splicing as a potential source of new
diagnostic, prognostic, predictive, and therapeutic tools against
human cancer. The global view of cancer-specific AS is not only
useful for exploring the complexity of the cancer transcriptome,
but it also widens the eyeshot of clinical research.
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